Paxman y Dignitana Anuncian Fusión para Crear Compañía Más Fuerte

Paxman and Dignitana, two leading medical technology companies specializing in scalp cooling systems, have announced their merger to form a stronger unified entity. This strategic move aims to capitalize on Paxman's leadership in the market and Dignitana's complementary strengths, enhancing innovation and expanding market reach, particularly in the United States. The merger will enable the combined company to increase coverage from 600 to 900 centers in the US, thus improving the management of chemotherapy side effects on a global scale. The unified company, Paxman AB, will focus on providing consistent service levels, enhancing R&D investment, and tapping into growth opportunities by expanding the market scope. The merger will also facilitate the introduction of a specialized Paxman device designed to prevent chemotherapy-induced peripheral neuropathy. The move is expected to enhance operational capabilities and solidify market presence, particularly in the US, with product launches anticipated in 2026.